Norris Medicines Stock Falls to 52-Week Low of Rs.14.5 Amidst Underperformance

Stock Price Movement and Market Context

On 1 Dec 2025, Norris Medicines traded down to Rs.14.5, its lowest level in the past year. This price point represents a substantial drop from its 52-week high of Rs.24.65, reflecting a decline of approximately 41.2%. The stock underperformed its sector by 3.02% on the day, with a day change of -3.33%. Notably, Norris Medicines is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating sustained downward momentum.

In contrast, the broader market has shown resilience. The Sensex opened higher at 86,065.92 points, gaining 359.25 points (0.42%) and was trading at 85,836.66 points (0.15%) during the same period. The Sensex is close to its 52-week high of 86,055.86, just 0.26% away, and has recorded a three-week consecutive rise, gaining 1.51% over this period. Small-cap stocks have also led the market, with the BSE Small Cap index gaining 0.34% on the day.

Financial Performance and Long-Term Trends

Over the past year, Norris Medicines has generated a return of -26.10%, significantly lagging behind the Sensex’s 7.52% gain. The company’s long-term financial indicators reveal challenges that have contributed to this performance. Net sales have shown a negative compound annual growth rate of -2.13% over the last five years, while operating profit has remained flat at 0% growth during the same period.

The company’s earnings before interest, taxes, depreciation and amortisation (EBITDA) have been negative, with the latest quarterly PBDIT reported at Rs.-0.49 crore. Profit before tax excluding other income (PBT LESS OI) stood at Rs.-0.72 crore, and earnings per share (EPS) for the quarter were Rs.-0.73, marking the lowest levels recorded recently. These figures highlight the subdued profitability and financial strain Norris Medicines is currently experiencing.

Balance Sheet and Debt Profile

Norris Medicines carries a high debt burden relative to its equity, with an average debt-to-equity ratio reported at 0 times, indicating a leveraged capital structure. The company’s book value is negative, which points to weak long-term fundamental strength. This financial positioning has likely contributed to the stock’s subdued market valuation and persistent downward pressure.

Comparative Performance and Valuation

When compared to its peers within the Trading & Distributors sector, Norris Medicines has underperformed over multiple time horizons. The stock’s returns have lagged behind the BSE500 index over the last three years, one year, and three months. Additionally, the company’s profits have declined by approximately 71% over the past year, underscoring the challenges faced in maintaining profitability.

The stock’s valuation metrics suggest it is trading at levels considered risky relative to its historical averages. This risk profile is reflected in the stock’s current market capitalisation grade, which is relatively low, and the predominance of non-institutional shareholders holding the majority stake.

Shareholding Pattern and Market Position

The majority of Norris Medicines’ shares are held by non-institutional investors, which may influence the stock’s liquidity and trading dynamics. The company operates within the Trading & Distributors sector, which has seen mixed performance relative to broader market indices. Despite the sector’s overall trends, Norris Medicines has not aligned with the positive momentum seen in indices such as the Sensex and BSE Small Cap.

Summary of Key Metrics

To summarise, Norris Medicines’ stock price has reached Rs.14.5, its lowest level in the past 52 weeks, reflecting a decline of over 40% from its peak. The company’s financial results show flat sales growth over five years, negative EBITDA, and a significant drop in profits over the last year. Its debt profile and negative book value further highlight financial constraints. Meanwhile, the broader market and sector indices have demonstrated relative strength, underscoring the stock’s divergence from prevailing market trends.

These factors collectively illustrate the current challenges faced by Norris Medicines in maintaining its market valuation and financial performance.

Limited Time Only! Upgrade now and get 1 Year of Stock of the week worth Rs. 14,999 for FREE. Don't miss out on this exclusive offer. Claim Your Free Year →